GlucoTrack Gains Approval for Long-Term Clinical Study

The latest update is out from GlucoTrack ( (GCTK) ).

On May 13, 2025, Glucotrack, Inc. announced it received ethical approval from the St. Vincent’s Hospital Melbourne Human Research Ethics Committee for a long-term clinical study of its continuous blood glucose monitor (CBGM) for individuals with type 1 and type 2 diabetes. The study, which will initially last one year with potential extensions to three years, aims to evaluate the device’s performance and safety, marking a significant advancement following a successful first-in-human study. This approval is a major milestone for Glucotrack, potentially enhancing its market position by offering a more accurate and less intrusive glucose monitoring solution that measures glucose directly from blood, unlike traditional systems.

Spark’s Take on GCTK Stock

According to Spark, TipRanks’ AI Analyst, GCTK is a Underperform.

GlucoTrack’s overall stock score is significantly impacted by its poor financial performance, characterized by a lack of revenue and negative equity. However, positive corporate events, including strategic partnerships and clinical advancements, provide some optimism. The technical analysis and valuation further emphasize the company’s current challenges, with bearish trends and poor valuation metrics. While speculative interest might arise from recent developments, the stock remains under pressure due to financial instability.

To see Spark’s full report on GCTK stock, click here.

More about GlucoTrack

Glucotrack, Inc. (NASDAQ: GCTK) is a medical device company focused on designing, developing, and commercializing novel technologies for people with diabetes. The company is currently developing a long-term implantable continuous blood glucose monitoring system.

Average Trading Volume: 5,696,178

Technical Sentiment Signal: Sell

Current Market Cap: $3.8M

See more data about GCTK stock on TipRanks’ Stock Analysis page.